News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
UK’s NICE Rejects GlaxoSmithKline, Genmab A/S Leukemia Drug, Arzerra
June 24, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- GlaxoSmithKline leukemia drug Arzerra, licensed from Denmark's Genmab, has been rejected by Britain's cost watchdog NICE in preliminary draft guidance.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
GlaxoSmithKline
MORE ON THIS TOPIC
Vaccines
FDA’s Makary Backs mRNA Vaccines but Says Companies ‘Can Fund Their Own Research’
February 24, 2026
·
2 min read
·
Tristan Manalac
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
February 23, 2026
·
3 min read
·
Nick Paul Taylor
Government
Kennedy Ally Departs CDC Amid Leadership Shake-Up
February 23, 2026
·
1 min read
·
Annalee Armstrong
Approvals
Vanda Rebounds From Jet Lag Rejection With FDA Nod for Bipolar, Schizophrenia Drug
February 23, 2026
·
2 min read
·
Tristan Manalac
